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ABSTRACT: Increasingly women at high risk of
breast cancer are opting for prophylactic surgery to
reduce their risks. Data from 10 European centres that
offer a risk counselling and screening service to
women at risk show different approaches to the option
of preventive surgery, although most centres adhere to
a protocol including at least two risk counselling
sessions and a psychological assessment. Thus far the
combined centres have data on 174 women who have
undergone prophylactic mastectomy with in excess of
400 women years of follow up. Operations were
carried out on women with lifetime risks of 25–80%,
with an average annual expected incidence rate of 1%
per women. No breast cancers have occurred in this
cohort. Long term follow up on an extended group of
women will be necessary to truly address the risk of
subsequent breast cancer and the psychological
sequelae.
INTRODUCTION
Management options available to women at
high lifetime risk of breast cancer due to their
family history, or to those women known to be
carrying a mutation in BRCA1/2 (which confer a
lifetime risk of breast cancer of 85% [1,2]) are
limited.  Screening with mammography is one
option, as is prophylactic mastectomy. The
efficacy of surgical procedures to reduce the risk
of breast cancer is controversial [3,4], although it
would appear that the residual risk of breast
cancer is dependent upon the amount of breast
tissue remaining following the surgical
procedure.  Recent work suggests that more
women are considering prophylactic mastectomy
[5,6] and that protocols should be in place to deal
with these requests.  It has been suggested that
surgery will increase life expectancy in BRCA1
or BRCA2 mutation carriers [7]. A recent study
by Hartmann et al. [8] has demonstrated that
women with a high risk of breast cancer can
significantly reduce the incidence of the disease
with prophylactic surgery. However, the level of
reduction in those at highest risk (BRCA1/
BRCA2 carriers) is still unclear.
In view of this, our European collaboration has
sought to develop protocols for women wishing
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to consider surgery and to assess the long-term
outcomes in terms of cancer prevention and
psychological sequelae.
Genetic counselling and the family history
clinic
Family history clinics have been established at
the ten participating centres (Table 1) between
1987 and 1992.  They are administered by
consultants in medical oncology, clinical genetics
and breast surgery often with a multidisciplinary
approach, with close involvement of radiologists,
and a psychiatrist/psychologist.
At the initial appointment, a risk assessment is
made from the family history using the Claus
data [9].  Women at a lifetime risk of breast
cancer of 1 in 6 or greater are offered
mammography and clinical examination on a 12–
18 monthly basis between the ages of 30–35 and
50 years. If appropriate, genetic testing is
discussed with women at this initial visit.  Three
of the centres (Manchester, Edinburgh,
Heidelberg/Dusseldorf) routinely mention the
possibility of prophylactic mastectomy to those
women with a lifetime risk of 1 in 4 or
greater.  This is often done with a single sentence
or a statement of the availability of the procedure
as an option for prevention of breast cancer.  This
then allows women to extend the discussion if
they wish to do so, or to state that they are not
interested in surgery.
THE PROPHYLACTIC MASTECTOMY
PROTOCOL
If women wish to discuss the procedure in
greater detail, most centres offer a further
appointment at least one month later.  This gives
women time to consider the procedure more fully
and to discuss it with appropriate members of the
family. Involvement of the partners in the
decision making process is usually encouraged
and they are, therefore, invited to attend each
appointment.  At the second appointment, with
the geneticist or oncologist, a basic description of
the surgery is given including the potential
residual risk of various procedures.  It is
emphasised that the residual risk and
complication rate may be higher if the surgery
preserves the nipple/areolar complex. It is also
usually made clear that these procedures are
largely unproven [3,4] as to their efficacy in
reducing the risk of breast cancer. The patient is
also challenged to consider the complications
which may result in a potentially poor cosmetic
result, as well as the possible impact upon her
personal life and family dynamics.
The possibility of genetic testing is also
discussed in terms of the availability of a living
affected member of the family and the basic
underlying structure of the family [10].  If
possible, a time scale for genetic testing is
discussed, and the woman is asked to consider
the potential impact of having proceeded with
Table 1
Number and type of prophylactic mastectomies carried out by centre
Centre No   Ages  (years) Mean SM MM Bilat Contralat BRCA1/2
Manchester 74 21–58 40 18 56 69  5 11
Edinburgh 34 32–60 43   0 34 15 19  2
Aberdeen 15 34–58 43.5   5 10 13  2  3
Leiden 15 20–37 36.5   8   7 15  0  ?
Dusseldorf 8 29–46 38   3   5   8  0  1
Oslo 12 27–51 39.5   6   6 11  1  0
Southampton 6 32–57 43.5   4   2   3  3  0
Belfast 5 32–57 40   5   0   2  3  1
Guys 5 28–37 34   2   3   4  1  1
Paris 4 28–51 40.5   2   2   1  3  0
No - number; Bilat - bilateral; contralat - contralateral; SM - simple mastectomy; MM - modified mastectomy (includes
subcutaneous).
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surgery if, later, she undergoes genetic testing
which shows that she does not carry the causative
mutation.  Centres also emphasise that the
genetic risk of breast cancer decreases with age
and that the remaining risk of breast cancer if the
women is older (over 40), is lower than the
lifetime risk [9].  If a woman wishes to proceed, a
psychological assessment is arranged.  At this
stage, confirmation of the breast cancers in the
family are proactively sought by most centres if it
has not already been completed. This ensures that
the risk assessment is as accurate as possible. In
one of our centres (Manchester) we have reported
the presence of factitious histories within some
families [11] and other centres, in confidence,
confirm this experience.
After a psychological assessment, a more
detailed surgical consultation is arranged to
discuss the type of procedure best suited to the
woman and whether a one or two stage procedure
is preferable.  This usually involves discussion of
3 basic options.  The first; total bilateral
mastectomy, the second; bilateral mastectomy
with reconstruction, either with implants or tissue
flaps, and the third; bilateral subcutaneous
mastectomy which retains the overlying skin and
nipple/areolar complex. The potential
complications are also discussed along with the
expected cosmetic result. Surgeons will usually
have photographs available for women to view if
they wish and may also arrange personal
meetings with one or more patients who have
already undergone bilateral mastectomy with
reconstruction.
The whole process of consultations through to
surgical procedure usually takes 6–12 months.
This time delay is deliberate, in most centres,
with the greatest delay at the beginning of the
protocol in order to allow women time for the
decision making process.  If the protocol is run
concurrently with a decision for predictive
genetic testing, then the wait will generally be
shorter. The number of women who are known to
have undergone prophylactic surgery in each
centre is shown in Table 1. The full protocol of
two sessions at the family history clinic, a session
with a psychiatrist and sessions with the surgeons
was established in 1993 in Manchester. While
only 2 other centres have a similar written
protocol the remaining clinics generally adhere to
the basic principles. The major difference is that
several centres are mainly reactive, meaning that
prophylactic surgery will usually be formally
discussed only with women proven to be
BRCA1/2 mutation carriers. No centre actively
recommends the procedure even in the latter
category.
There is no clear pattern in terms of the
surgical procedure recommended in women who
have decided on surgery. While some units are
cautious about offering skin/nipple-preserving
mastectomies, these options are generally
available in every case.
FOLLOW-UP
Follow up of women who have undergone
surgery is considered an important part of the
protocol in each centre. In Manchester, women
who have undergone prophylactic mastectomy
are followed up annually at a “multidisciplinary
day”.  As well as discussion of problems/issues
with all the relevant clinicians (Geneticist/
oncologist/psychiatrist/surgeons), each patient is
examined.  Clinical examination by palpation of
the breasts is felt to be adequate as remaining
breast tissue is very superficial in all types of
surgical procedure.  Thus far, no cancers have
occurred prospectively in the 174 women who
have undergone surgery. Using data from Claus
[9] and the International Linkage Consortium [1]
it is possible to calculate annual age dependant
expected incidence rates for breast cancer in
women who have not undergone surgery. The
mean expected rate for our cohort of women is
1% annually, reflecting a lifetime risk that ranged
from 25–80%. Even though this cohort already
has a follow up in excess of 400 woman years,
only 4 cancers would have been expected. Follow
up of an extended cohort for more than 5 years
will be necessary to address the issue of risk
reduction. If this is to be analysed by type of
surgery or by confining to known BRCA1/2
mutation carriers, (currently only 17/174) even
longer follow up will be necessary.
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